EVOLENT HEALTH ($EVH) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.02 per share, beating estimates of -$0.05 by $0.03. The company also reported revenue of $496,250,000, missing estimates of $540,015,215 by $-43,765,215.
You can see Quiver Quantitative's $EVH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EVOLENT HEALTH Insider Trading Activity
EVOLENT HEALTH insiders have traded $EVH stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EVH stock by insiders over the last 6 months:
- BRENDAN B SPRINGSTUBB purchased 10,000 shares for an estimated $38,199
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
EVOLENT HEALTH Hedge Fund Activity
We have seen 110 institutional investors add shares of EVOLENT HEALTH stock to their portfolio, and 132 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 8,735,926 shares (-99.8%) from their portfolio in Q4 2025, for an estimated $34,943,704
- EVENTIDE ASSET MANAGEMENT, LLC removed 6,292,511 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,170,044
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 4,035,475 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $16,141,900
- D. E. SHAW & CO., INC. added 2,531,506 shares (+92.5%) to their portfolio in Q4 2025, for an estimated $10,126,024
- VANGUARD GROUP INC removed 2,052,765 shares (-18.7%) from their portfolio in Q4 2025, for an estimated $8,211,060
- UBS GROUP AG added 2,040,743 shares (+33.4%) to their portfolio in Q1 2026, for an estimated $4,652,894
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 1,799,081 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $7,196,324
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
EVOLENT HEALTH Analyst Ratings
Wall Street analysts have issued reports on $EVH in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/25/2026
- Citigroup issued a "Buy" rating on 11/21/2025
- JP Morgan issued a "Overweight" rating on 11/17/2025
- Canaccord Genuity issued a "Buy" rating on 11/14/2025
- BMO Capital issued a "Outperform" rating on 11/13/2025
- Citizens issued a "Market Outperform" rating on 11/10/2025
- Truist Securities issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for EVOLENT HEALTH, check out Quiver Quantitative's $EVH forecast page.
EVOLENT HEALTH Price Targets
Multiple analysts have issued price targets for $EVH recently. We have seen 11 analysts offer price targets for $EVH in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Michael Wiederhorn from Oppenheimer set a target price of $6.0 on 03/02/2026
- Jailendra Singh from Truist Securities set a target price of $6.0 on 02/26/2026
- Kevin Caliendo from UBS set a target price of $5.0 on 02/26/2026
- Daniel Grosslight from Citigroup set a target price of $4.0 on 02/26/2026
- David Larsen from BTIG set a target price of $8.0 on 02/25/2026
- Ryan Halsted from RBC Capital set a target price of $3.0 on 02/25/2026
- Matthew Shea from Needham set a target price of $4.0 on 02/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
